GlassScriptPhysician profile
Carrie B Hodges
NPI 1164853461
$2,770.89
in general payments reported to CMS, 2019-2025
24 companies · $638 in 2025
The $638 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $148 · 2022: $550 · 2023: $849 · 2024: $585 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $376.70 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Mayne Pharma Commercial LLC | $357.73 | 2022-2025 | |
| Abbvie INC. | $286.06 | 2021-2023 | |
| Biogen, INC. | $225.27 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $192.45 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $173.78 | 2021-2024 | Slynd |
| Evofem Biosciences, INC. | $163.95 | 2021-2025 | Phexxi, Solosec, Phexx |
| Shockwave Medical, INC | $155.58 | 2025 | |
| Organon LLC | $130.25 | 2022-2024 | Nexplanon |
| Shield Therapeutics INC | $103.21 | 2024 | |
| Therapeuticsmd, INC. | $92.20 | 2021-2022 | |
| Axonics, INC. | $79.50 | 2023 | Axonics |
| Coloplast Corp | $70.44 | 2024-2025 | |
| Exact Sciences Corporation | $69.22 | 2023-2025 | Cologuard Collection Kit |
| Avion Pharmaceuticals | $64.03 | 2023 | Balcoltra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $38.22 | 2022-2023 | Novasure |
| Sumitomo Pharma America, INC. | $38.07 | 2024 | Gemtesa, Myfembree |
| Idorsia Pharmaceuticals US INC | $30.28 | 2023 | Quviviq |
| Ascend Therapeutics US, LLC | $26.66 | 2023 | |
| Scynexis, INC. | $25.59 | 2022 | |
| Lilly USA, LLC | $23.84 | 2024 | Zepbound |
| Acella Pharmaceuticals, LLC | $17.89 | 2025 | NP Thyroid 60 |
| Millicent US INC | $16.10 | 2023 | Intrarosa |
| Currax Pharmaceuticals LLC | $13.87 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Hodges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.